Hims and Novo Nordisk partner to offer discounted Wegovy
In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight loss drug Wegovy at a discounted price directly through the telehealth...
View ArticleDevoted Health 2024 financials reveal revenue growth
Health insurance startup Devoted Health is a bright spot in the volatile market for private health plans for seniors, growing membership and revenue while narrowing its operating losses in 2024, even...
View ArticleWith a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership
Creyon Bio, a small San Diego biotech startup working on oligonucleotides, has signed up Eli Lilly as its first big pharma partner. The Indianapolis giant, which has placed more of an emphasis on...
View ArticleAbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder...
Plus, news about the Novo Nordisk Foundation and Tonix: AbbVie’s Rinvoq gets label expansion: The blockbuster JAK inhibitor won approval in the US to treat adults with giant cell arteritis, an ...
View ArticleFDA won't reorganize medical product centers, Makary says in interview
The FDA plans to consolidate some administrative functions, but won't embark on a wholesale reorganization of the review centers that oversee drugs, biologics and medical devices, FDA Commissioner...
View ArticleFDA approves Abeona’s skin disease cell therapy
Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes fragile skin and wounds. And its price tag makes it one of the most...
View ArticleMerck plans to shift Keytruda production to the US
Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on its plans to move production to the US to mitigate the impact of potential...
View ArticleInside Devoted Health’s 2024 financials
Every spring I ask Shelby a very fun question: Is it time to look at insurance filings? This year, that included combing through the 33 individual filings. Together, they give a rare glimpse into how ...
View ArticleHow pharma is reacting to ‘Liberation Day’: Endpoints livestream
Tomorrow at 12 p.m. ET, we’re going to try something new. We’re taking Post-Hoc — our newsletter that brings you insight from our journalists — and streaming it live! We'll talk about how the drug...
View ArticlePfizer’s Bourla projects confidence that tariffs will focus on US adversaries
With the Trump administration's planned pharma tariffs on the horizon, Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented....
View ArticleArtios cancer drug shrinks subset of tumors in early study
Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer. It’s the first big data reveal for...
View ArticleNoma Therapy raises $4M for virtual ketamine-assisted therapy
Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News learned exclusively. The Colorado-based startup is backed by health tech studio...
View ArticleGSK's supply chain 'reset' after Haleon spinoff to ease tariff impact, CEO says
GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential pharma-specific tariffs. When the drugmaker went through its “demerger” with the ...
View ArticleUpdated: Novartis to buy Regulus Therapeutics for up to $1.7B
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. The biotech’s share price {$RGLS} jumped more than 135% in premarket...
View ArticleFDA approves Johnson & Johnson's rare disease drug that's expected to compete...
The FDA approved a new rare disease drug that Johnson & Johnson hopes can compete with established medicines — and some that are yet to be approved — and become a megablockbuster. Regulators on...
View ArticleImmunic’s stock falls on multiple sclerosis data; Entrada’s layoffs
Plus, news about Henlius, Sandoz, Cellectar Biosciences, Ono Pharma and Altamira Therapeutics: Immunic’s Phase 2 multiple sclerosis readout: The company said vidofludimus calcium (IMU-838) reduced the...
View ArticleEndpoints Slack interview: Arc Institute's Patrick Hsu on AI bio, investing
Science is full of wunderkinds. But 31-year-old Patrick Hsu has already been on the frontiers of academic science, the biotech industry and now the world of nonprofit research. Hsu started doing lab...
View Article#AACR25: Scientists alarmed about future of cancer research
CHICAGO — Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science funding will have an unprecedented impact on the future of cancer...
View ArticleRegeneron loses bid to fend off false claims fight over Eylea
Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded the US out of hundreds of millions of dollars. On Tuesday, a federal judge...
View Article